Related Experiment Videos
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas
M D Caballero1, M L Amigo, J M Hernández
1Servicio de Hematología, Hospital Universitario de Salamanca, Spain.
Annals of Hematology
|February 1, 1997
Summary
Combining mini-BEAM and ESHAP chemotherapy for refractory non-Hodgkin's lymphoma (NHL) showed a 39% response rate. This alternating regimen was effective for relapsing or partial responders but not for primary refractory patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Mini-BEAM and ESHAP are established salvage chemotherapy regimens for lymphoma.
- Non-cross-resistant regimens are crucial for managing refractory lymphoma.
- Evaluating novel combinations can improve treatment outcomes.
Purpose of the Study:
- To assess the efficacy and safety of alternating mini-BEAM and ESHAP cycles as salvage therapy for refractory non-Hodgkin's lymphoma (NHL).
Main Methods:
- A total of 28 refractory NHL patients received alternating cycles of mini-BEAM and ESHAP.
- Treatment continued until maximum response or disease progression.
- Patients who responded were considered for autologous stem cell transplantation consolidation.
Main Results:
- The overall response rate was 39%, with 25% complete responses and 14% partial responses.
- No primary refractory patients responded to the combined regimen.
- Three-year survival was 64% for responders consolidated with autologous transplantation.
- Myelosuppression was the most common toxicity; no treatment-related deaths occurred.
Conclusions:
- Alternating mini-BEAM/ESHAP is a safe salvage regimen for NHL patients with sensitive relapsing or partial response disease.
- The combination is not effective in primary refractory NHL.
- This approach does not appear to offer superior outcomes compared to ESHAP alone.